Temporary hair loss is a common side effect of chemotherapy drugs. It’s not unusual for cancer patients to lose their hair while undergoing treatment and then watch it grow back after they stop taking the medications. Sanofi-Aventis did not warn patients or doctors about the side effect of permanent hair loss from taking Taxotere. Patients took unnecessary risks.

What is Taxotere?

Taxotere (Docetaxel) is a chemotherapy drug manufactured and marketed by Sanofi-Aventis. Doctors prescribe the drug to treat the majority of breast cancer cases in the U.S. The treatment plan for Taxotere is once every three weeks, unlike Paclitaxel, a drug in the same class, which is weekly and just as effective.

Taxotere Lawsuit

The Taxotere lawsuit states that Sanofi-Aventis failed to warn patients and physicians of the increased risks of permanent alopecia (loss of hair) through the use of Taxotere during chemotherapy. Sanofi Aventis warned other countries about the alopecia risk but did not warn women in the U.S.

What is Permanent Alopecia

An untreatable medical condition in which the body’s immune system attacks its own hair follicles. The absence of new growth after six months to a year points to permanent hair loss. Skin without new growth appears smooth and shiny.